In addition to the CD19-targeting CAR-T therapy, two CAR-T products targeting BCMA have also been approved by FDA for the treatment of R/R multiple myeloma (MM) after four or more lines of systemic therapy. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.